Alimera Sciences (ALIM) Earns Daily News Sentiment Score of 0.26
Media headlines about Alimera Sciences (NASDAQ:ALIM) have been trending positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Alimera Sciences earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 46.4316373719691 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- North America Will Remain Dominant in the Global Diabetic Macular Edema Market (medindia.net)
- Alimera Sciences’ CEO Dan Myers to Present U.S. Real-World ILUVIEN® Post-Marketing Data During Ophthalmology Innovation Summit at ASRS, August 10, 2017 (finance.yahoo.com)
- HC Wainwright Reiterates “$5.00” Price Target for Alimera Sciences, Inc. (NASDAQ:ALIM) (americanbankingnews.com)
- Alimera Sciences’ (ALIM) CEO Dan Myers on Q2 2017 Results … – Seeking Alpha (seekingalpha.com)
- Alimera Sciences, Inc. (NASDAQ:ALIM) Given a $3.00 Price Target by Cowen and Company Analysts (americanbankingnews.com)
ALIM has been the subject of a number of research reports. Rodman & Renshaw initiated coverage on Alimera Sciences in a report on Thursday, April 27th. They issued a “buy” rating and a $4.00 price objective for the company. Cowen and Company reiterated a “buy” rating and issued a $3.00 price objective on shares of Alimera Sciences in a report on Tuesday, July 11th. Zacks Investment Research upgraded Alimera Sciences from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Monday, July 10th. HC Wainwright set a $5.00 price objective on Alimera Sciences and gave the stock a “buy” rating in a report on Tuesday, July 11th. Finally, ValuEngine upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $3.38.
Alimera Sciences (ALIM) opened at 1.56 on Tuesday. The stock’s 50 day moving average price is $1.42 and its 200 day moving average price is $1.38. Alimera Sciences has a one year low of $1.03 and a one year high of $2.40. The company’s market capitalization is $101.25 million.
Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The company had revenue of $10.40 million for the quarter, compared to analysts’ expectations of $10.20 million. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. During the same quarter last year, the company earned ($0.17) earnings per share. Equities analysts anticipate that Alimera Sciences will post ($0.21) EPS for the current fiscal year.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.